CytomX Therapeutics Earning Date (CTMX)

USA |NASDAQ |USD

CTMX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.30
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $16.29M

Cytomx Therapeutics's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

CTMX Earnings Date & History Chart

CTMX Earnings & Revenue Forecast

CTMX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $-1.57 $-2.20 $-1.01

CTMX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 3 $-1.56 $-1.54 $-1.49

CTMX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $72.42M $0.00 $116.05M

CTMX Earnings Date & Revenue History

CTMX Earnings History

|
Show More
Show More

CTMX Revenue History

|
Show More
Show More

Cytomx Therapeutics Next Earnings Date & Report

CTMX Next Earnings Date & Report Preview: Jun 2022 (FQ)

CTMX's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Cytomx Therapeutics Previous Earnings Dates & Reports

CTMX Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Cytomx Therapeutics's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.

CTMX Previous Earnings Date & Report Recap: Dec 2021 (FY)

Cytomx Therapeutics's previous annual earnings date was Mar 1, 2022 for its fiscal year ended Dec 31, 2021.

CTMX's earnings per share (EPS) was $-1.31, missing the consensus analysts forecast of $-1.19 by 10.08% , and lower than the previous year's EPS (Dec 2020) by 84.51%.

Revenues were $69.57M, worse than the forecast of $74.36M by -6.44%, and down by -30.68% from previous year's revenue.

The company reported a net income of $-83.61M.

Cytomx Therapeutics reported a free cash flow of $-120.64M for its fiscal year, compared to $2.95M a year ago.